Oneness Biotech and Microbio Shanghai's SNS812, the world's first fully modified siRNA drug administered via aerosol inhalation, has been selected for oral presentation at the 2025 ATS International Conference.
Oneness Biotech and Microbio (Shanghai)'s SNS812 achieved statistically significant and clinically meaningful endpoints in a Phase 2 trial for COVID-19 treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.